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Studies aimed to elucidate the pathogenesis of the disease and to ﬁnd new therapeutic options for
multiple sclerosis (MS) patients heavily rely on experimental autoimmune encephalomyelitis (EAE)
as a suitable experimental model. This strategy has been highly successful for the inﬂammatory
component of the disease, but had so far little success in the development of neuroprotective ther-
apies, which are also effective in the progressive stage of the disease. Here we discuss opportunities
and limitations of EAE models for MS research and provide an overview on the complex mecha-
nisms leading to demyelination and neurodegeneration in this disease. We suggest that the under-
lying mechanisms involve adaptive and innate immunity. However, mitochondrial injury, resulting
in energy failure, is a key element of neurodegeneration in MS and is apparently driven by radical
production in activated microglia.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Multiple sclerosis is a complex chronic immune mediated dis-
ease of the central nervous system (CNS; [63]). Its etiology is cur-
rently unknown and its pathogenesis is only partly understood.
Complex genetic traits as well as environmental factors determine
the susceptibility to develop the disease and the respective results
indicate that immune mechanisms play an essential role in driving
the disease process [48]. Major support for an autoimmune
hypothesis comes from studies of experimental autoimmune
encephalomyelitis (EAE), a disease in animals, which can be
induced by sensitization with CNS antigens [46]. EAE shares clini-
cal and pathological features with MS [65], and in particular by
immunologists EAE is generally accepted as the animal model for
MS [35]. Thus, when searching medical databases for publications
of the last decades related to the pathogenesis of MS, the vast
majority of the respective studies describe disease mechanisms
in EAE animals. This approach was in part highly valuable, as it
uncovered basic mechanisms of immune surveillance of the CNS
and the molecular events that allow leukocytes to pass the blood
brain barrier and to induce brain inﬂammation [30,35,46]. Further-
more, it shed light on different pathways of tissue injury triggered
by immune reactions in the CNS. It is now well accepted that thesecal Societies. Published by Elsevier
.at (H. Lassmann), j.vanhors-studies form the background, on which modern anti-inﬂammatory
and immunomodulatory treatments, which are effective in MS
patients, have been developed. However, there were also major
disappointments [111]. Quite a signiﬁcant number of therapies,
which were potential candidates from EAE studies, failed the test
of human trials. Prominent examples for divergent results between
EAE models and human trials are treatments with tumor necrosis
factor alpha (TNF) blockers [99], with gamma-interferon [85] or
the blockade of Th1/Th17 pathways [91]. This is even worse for
‘‘neuroprotective’’ therapies, for which so far none has been proven
to be effective in MS patients. One potential reason for this disap-
pointing situation may be that the pathogenesis of the disease, in
particular in the progressive stage, is more complex than that of
current EAE models and seems to involve mechanisms of innate
immunity in the process of neurodegeneration [110]. In addition,
chronic inﬂammation in the MS brain may provoke additional
autoimmune responses directed against antigens different from
those tested in classical models of EAE [25]. For these reasons,
much more effort has to be invested to study the disease process
of MS with particular focus on immunological and molecular
events, which take place in the brain and spinal cord lesions of
the patients themselves, and to reﬂect these ﬁndings on the basis
of knowledge, obtained in EAE models before.
2. Basic features of MS pathology
Multiple sclerosis is a chronic inﬂammatory disease of the CNS.
Its pathology was originally deﬁned by the presence of focal whiteB.V. Open access under CC BY-NC-ND license.
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tial preservation of axons and reactive astrocytic scar formation
[64]. Although axons are quite well preserved within the lesions
in comparison to the complete demyelination, they too are affected
[29,56,100] and axonal loss has been shown to be a major correlate
of permanent neurological deﬁcit in MS patients [11]. In the early
stages of the disease, when patients present with clinical relapses
and remissions inﬂammatory demyelination leads to the formation
of focal plaques, which are predominantly located in the white
matter. In later stages of the disease, dominating in patients with
secondary or primary progressive disease, additional pathology is
seen, which includes widespread demyelination in the cerebral
and cerebellar cortex as well as diffuse degenerative changes
throughout the entire white and grey matter [60]. This ﬁnally re-
sults in patients with longstanding severe disease in profound
brain and spinal cord atrophy with extensive tissue loss and dilata-
tion of cerebral ventricles. Thus, while the disease process starts
with inﬂammation driven focal demyelinating lesions, which arise
around small drainage veins in the white matter, in time diffuse
neurodegeneration ensues which affects the entire CNS (Fig. 1).
3. Inﬂammation
Chronic inﬂammation is one of the major hallmarks of multiple
sclerosis pathology. It starts at small veins and venules and areas
with high density of such vessels are preferential sites for initial
MS lesions [74]. Inﬂammatory inﬁltrates are composed of lympho-
cytes. The vast majority of them are MHC Class I restricted CD8+
T-cells, which also show dominant clonal expansion within the
lesions [2]. MHC Class II restricted CD4+ T-cells as well as B-cells
or Plasma cells are mainly seen in perivascular spaces and in the
meninges, whereas their inﬁltration into the compact tissue of
the central nervous system is sparse. Active tissue injury in MS le-
sions is associated with activated microglia and inﬁltrated macro-Fig. 1. The pathology of multiple sclerosis changes with time. In the early phase of the di
This is associated with bouts of clinical disease (black line) and many new lesions on MR
diffuse white matter injury is seen in addition to focal white matter lesions. This result
dashed line). At very late stages the disease burns out in a substantial number of patients
seen in age matched controls. During stages of active disease, both in the relapsing as w
that in early stages oxidative damage is mainly driven by inﬂammation, resulting in
neurodegeneration occurs on the background of mild to moderate inﬂammation, but oxid
the burnt out stage the presence of iron in the brain in the absence of additional oxida
patients may become affected by concomitant diseases such as stroke or Alzheimer’s diphages [49]. Although, overall the inﬂammatory reaction in MS
lesions, mainly consisting of T-cells and activated microglia/
macrophages, is similar compared to that seen in the classical
EAE models [35,65], there are three differences, which have to be
considered. In most EAE models, which are driven by Th1 or
Th17 cells, inﬂammation starts with profound inﬁltration of the
tissue by MHC Class II restricted CD4+ T-cells, which is followed
by microglia activation and macrophage recruitment into the
lesions [30]. Recruitment of CD8+ T-cells generally happens a few
days after the initial T-cell inﬁltration [44]. In contrast, in MS le-
sions - irrespective their stage of development - it is the CD8+ T-cell
population, which always predominates and shows preferential
clonal expansion. Secondly, two waves of T-cell inﬁltrates are seen
in MS lesions in the course of lesion maturation [42,80]. In lesions
with initial oligodendrocyte injury, demyelination and tissue
injury massive pro-inﬂammatory microglia activation is present,
associated with only a minor inﬁltration of T-cells, which are
nearly exclusively MHC Class I restricted CD8+ cells. However,
when myelin has fallen apart and been taken up by activated
microglia and macrophages a massive second wave of leukocyte
inﬁltration is seen, which also consists predominantly of CD8+
cells, but contains additional CD4+ cells and B-cells [6,42,80].
Thirdly, there is accumulating evidence that with progression of
the disease the inﬂammatory response within the CNSmay change.
It decreases in severity with age of the patients and disease dura-
tion, but active demyelination and neurodegeneration is invariably
associated with inﬂammation, consisting of T-cells, B-cells, Plasma
cells and activated microglia and macrophages [34]. At very late
stages of the disease inﬂammation may decrease to levels seen in
controls and in these patients acute axonal injury too decreases
to levels seen in the matched controls [34]. In addition, new evi-
dence suggests that inﬂammation becomes at least partly trapped
behind a closed or repaired blood brain barrier in patients with pri-
mary or secondary progressive MS. This is reﬂected by perivenoussease white matter lesions dominate (green: demyelinated and blue: remyelinated).
I (green arrows). In the progressive stage massive cortical demyelination (red) and
s in profound brain atrophy (blue dotted line) and reduction of brain volume (red
. Inﬂammation as well as neurodegeneration in these patients has declined to levels,
ell as in the progressive stages, profound oxidative tissue injury is seen. We suggest
oxidative burst in microglia and macrophages. In the progressive stage active
ative damage seems to be augmented by release of iron from intracellular stores. In
tive burst from microglia does not lead to further neurodegeneration, although the
sease.
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endothelial cells or serum protein leakage through the blood brain
barrier [45]. Furthermore, dense aggregates of inﬂammatory cells,
which may organize in structures and resemble features of second-
ary lymph follicles, are seen in the meninges and, less prominently,
in the large perivascular Virchow Robin spaces [92]. Interestingly,
this compartmentalized meningeal inﬂammation seems to be the
driving force for active demyelination as well as neuronal, axonal
and synaptic destruction in the cerebral cortex of MS patients
[75,76], although this concept still needs independent conﬁrma-
tion. So far these MS typical features of inﬂammation are not or
only rudimentarily reﬂected in the pathology of EAE. These differ-
ences may in part explain failures of therapeutic strategies, devel-
oped in EAE models [32] and may also provide a reason for the lack
of efﬁcacy of anti-inﬂammatory treatment in patients with pro-
gressive MS. Thus, treatments, which target pro-inﬂammatory
mechanisms mediated by CD8+ T-cells may turn out to be more
efﬁcient compared to those speciﬁcally targeting MHC Class II re-
stricted T-cell responses [33]. However, experimental studies in
EAE show that targeting CD8+ T-cells may increase disease and
inﬂammation, possibly by eliminating Class I MHC restricted regu-
latory T-cells [17,18], and treatments studies in models of CD8+ T-
cell mediated brain autoimmunity are currently not available. A
particularly interesting study in this context showed increased
neurodegeneration in EAE in beta-2 microglobulin deﬁcient mice,
which, however, was not dependent upon MHC Class I restricted
immune responses [68]. Beta-2 microglobulin deﬁciency not only
affects MHC Class I restricted T-cell responses but also leads to
general iron overload resembling hemochromatosis [81,89]. As dis-
cussed below, iron overload in the central nervous system may be
one additional factor propagating neurodegeneration.
A similar problem has been reported with B-cell depleting anti-
body treatment. Therapeutic trials with anti-CD20 antibodies have
shown signiﬁcant and quite pronounced effects in MS patients
[5,41]. In EAE similar treatments resulted in either beneﬁcial or
detrimental effects, dependent upon the model used [109]. Back-
ground immunological data suggest that in situations of pure T-cell
mediated inﬂammation, e.g. after sensitization with the major
encephalitogenic T-cell epitope of myelin oligodendrocyte glyco-
protein, B-cell depletion enhances disease possibly through elimi-
nation of regulatory B-cells. In contrast, in other EAE models B-cells
appear to be important for antigen presentation and T-cell priming,
thus resulting in profound amelioration of diseases after B-cell
elimination. It is currently unknown, how this relates to treatment
of MS patients and how it could be predicted on the basis of the
data, obtained in the experimental models.
Thus, regarding inﬂammation the detailed knowledge on leuko-
cyte trafﬁcking into the CNS and the mechanisms of brain inﬂam-
mation, which was obtained in experimental models and well
validated in pathological studies in MS patients, paved the way
for our currently available anti-inﬂammatory and immunomodula-
tory treatments. There are, however, signiﬁcant differences in the
inﬂammatory reaction between MS patients and EAE animals.
Thus, before starting clinical trials with new anti-inﬂammatory
compounds careful validation of the role and importance of the
speciﬁc targets in MS patients is mandatory. In addition, for the
treatment of MS patients in the late progressive stage it will be a
prerequisite that the respective compounds have access to the
CNS through an intact blood brain barrier.
4. Demyelination and neurodegeneration
The architecture of an active MS lesion is highly complex [61].
What is generally considered as an active MS lesion is a plaque,
which is ﬁlled with macrophages, which have taken up anddegrade the remnants of the destroyed myelin sheaths [14]. This
is, however, a rather late stage in the development of the lesion,
where active tissue injury is already accomplished and remyelina-
tion or reparative mechanisms might already be triggered. Initial
tissue injury occurs within a small rim, which extends from the
margin of the plaque into the surrounding periplaque white matter
[61]. Such a zone of initial tissue injury is present in some, but by
far not in all putatively active MS lesions, reﬂecting their ongoing
expansion at the time point of the patient’s death. It is, however,
important to note that only in such lesion areas, also called the
‘‘prephagocytic’’ stage of MS lesion formation [6], mechanisms of
demyelination or neurodegeneration can be identiﬁed. As men-
tioned before, such areas of initial tissue injury in MS show a low
grade of lymphocyte inﬁltration (nearly exclusively by CD8+ T-
cells) and microglia activation. These data suggest that activated
microglia play a central role in the neurodegenerative process.
It is well known from the earliest studies on MS pathology that
myelin and its supporting cells, the oligodendrocytes, are preferen-
tially destroyed in the lesions in comparison to other CNS elements
[3]. It was, thus, for long time believed and is still postulated in
many recent publications that MS is an autoimmune disease, in
which the immune reaction is directed against one or more myelin
antigens. This simplistic view, however, is misleading. Autoimmu-
nity, mediated by Class II restricted T-cells, shows very similar pat-
terns of inﬂammation and tissue injury in the CNS, regardless
whether it is directed against myelin, neuronal or astrocytic anti-
gens, although the distribution of the lesions within the CNS may
vary in an antigen speciﬁc manner [9,54,58]. The situation is differ-
ent for immune mediated damage by Class I restricted CD8+ T-cells
or by speciﬁc autoantibodies. In these situations the immune re-
sponse leads to selective destruction of target cells, which contain
the respective antigen (or epitope; [66,90]. Indeed, inﬁltration of
active MS lesions by CD8+ T-cells, which show cytotoxic activation
and interaction with oligodendrocytes or axons is sometimes seen,
but this is a rare event, restricted to a subset of patients with very
aggressive disease and lesions (Marburg’s type of acute MS; [83].
Little is currently known regarding autoimmune reactions of Class
I restricted T-cells in MS patients in relation to disease course,
activity and lesional pathology. Similarly, MS lesions may show lo-
cal deposition of immunoglobulins and activated complement at
sites of active demyelination, but also this is only seen in a subset
of patients [73]. Autoantibodies, directed against the target epitope
of myelin oligodendrocyte glycoprotein, which is recognized in the
process of demyelination, have been detected in a small subset of
MS patients, which mainly consists of children with atypical
disease course [13]. Other molecular targets for demyelinating
antibodies are glycolipids, but their pathogenic potential in
inﬂammatory demyelinating lesions is less clear. Thus, speciﬁc
pathogenic immune responses against myelin or other CNS compo-
nents may be restricted to a subgroup of MS patients, raising the
question, whether the selective type of tissue injury, characteristic
for all MS lesions, can be explained by alternative mechanisms.
5. Mitochondrial Injury in MS Lesions
To discuss this possibility we ﬁrst have to understand the spe-
ciﬁc features of tissue damage in MS lesions. Demyelination is
the hallmark of the lesions, and it has been shown more recently
that it is preceded by destruction of oligodendrocytes through
apoptosis [6,73]. In addition, axonal loss is present in all lesions
and its extent varies between different lesions and patients [55].
Thin axons are preferentially destroyed, while thick axons in gen-
eral survive [28]. Remyelination may occur, but in the majority of
the patients it is impaired [87], even when oligodendrocyte pro-
genitor cells are present [16]. Astrocytes are also affected within
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molecules, which are normally expressed in the most peripheral
processes, forming the perivascular and subpial glia limiting mem-
brane [86,95]. Thus, in essence all cellular components of the CNS
are affected in MS lesions, albeit in quantitatively variable extent.
To explain such a scenario by a single mechanism cell type speciﬁc
vulnerability has to be postulated. Interestingly, the tissue altera-
tions, present in fulminant active MS lesions, are strikingly similar
to those seen in fresh lesions of patients with an acute white mat-
ter stroke [1]. These data place energy deﬁciency in the center of
interest, when discussing neurodegeneration in MS patients.
In line with this concept recent data identiﬁed mitochondrial
injury with subsequent energy deﬁciency as an important compo-
nent of MS pathogenesis [78,101,113]. Profound mitochondrial dis-
turbances have been found in MS lesions by microarray based gene
expression analysis [26,27], by immunohistochemistry, biochemi-
cal analysis and by electron microscopy [26,79,112]. In acute and
active lesions ﬁrst changes in mitochondria are reﬂected by a dom-
inant loss of immunoreactivity of cytochrome C oxidase (COX1)
and loss of the respective complex IV activity of the mitochondrial
respiratory chain [79]. In contrast, in chronic inactive lesions mito-
chondrial numbers and activity are increased, apparently reﬂecting
the higher energy demand of demyelinated compared to myelin-
ated axons [77]. Tissue injury due to mitochondrial dysfunction
can be induced in principle by three different mechanisms: energy
failure, the induction of apoptosis and enhanced production of
reactive oxygen species. Mitochondrial injury can trigger pro-
apoptotic events, for instance by the liberation of apoptosis-induc-
ing factor (AIF) or cytochrome C. This apparently represents an
important pathway of oligodendrocyte destruction and demyelin-
ation [106]. Energy failure provides a good explanation for other
aspects of MS pathology. It explains the preferential destruction
of small caliber axons, resulting in disturbed ion clearance from
the axoplasm, Ca++ accumulation and axonal demise predomi-
nantly in those axons with low mitochondrial content and large
axonal surface area [98]. In oligodendrocyte progenitor cells mito-
chondrial injury results in an impaired maintenance of cell pro-
cesses and differentiation into myelinating cells resulting in
remyelination failure [116]. This is in line with previous studies
indicating an important role of inﬂammatory factors and differen-
tiation block of oligodendrocyte progenitor cells in remyelination
failure in MS [57,59]. A similar mechanism may underlay the dis-
turbance of astrocyte polarity in active MS lesions. Importantly, re-
cent ﬁndings demonstrate the occurrence of extensive neuronal
mtDNA deletions in MS cortex [15]. The cause of these mtDNA
alterations might be ongoing microglial activation, but this has to
be proven yet. Nonetheless, it is conceivable that respiratory-deﬁ-
cient mitochondria in affected neurons signiﬁcantly contribute to
neurodegenerative processes underlying MS progression. Thus, ta-
ken together the complex pathological alterations, which occur
side by side within active MS lesions, can in principle be explained
by a single mechanism, which involves mitochondrial injury and
dysfunction.
6. Oxidative Damage in MS Lesions
Mitochondria are highly susceptible for oxidative damage either
through direct affection of the mitochondrial respiratory chain or
by the induction of pro-apoptotic mechanisms. Nitric oxide pre-
dominantly affects the COX1 molecule of Complex IV [12] and to-
gether with reactive oxygen species (ROS) can target the
respiratory chain complexes at several different levels [96,97]. In
addition ROS may induce mitochondrial permeability transition
and, thus, trigger the apoptotic cascade. For these reasons, oxidative
damage may explain at least in part the profound mitochondrialdefects in active MS lesions. Several studies have analyzed radical
mediated tissue injury in MS lesions biochemically and through
the immunocytochemical identiﬁcation of oxidized nucleotides,
proteins or lipids [104]. The results suggested increased oxidative
injury in MS brains, although not all studies were able to show sig-
niﬁcant differences between MS and control tissue [4,10,24,69,
71,88,105,107]. Furthermore, on a cellular basis oxidized epitopes
were mainly seen in macrophages and astrocytes, cells which are
not the prime target of destruction within the lesions [69,24,105].
A possible explanation for these conﬂicting results may be that no
speciﬁc emphasis was paid on the analysis of initial stages of lesion
formation. In line with this interpretation is a study, which ana-
lyzed nitrotyrosine in well deﬁned active lesions, where it was
found to be present in oligodendrocytes [115]. We have recently
addressed this question in more detail by analyzing a large sample
of well deﬁned lesion stages from patients with fulminant acute as
well as chronic MS [40]. In this material profound immunoreactiv-
ity for oxidized DNA and lipids was found in active and slowly
expanding lesions, where it was predominantly present in the areas
of initial tissue injury. Furthermore, in these lesion areas oxidized
DNA and lipids were mainly present in oligodendrocytes, some of
them showing nuclear alterations of apoptosis. In addition, pro-
nounced accumulation of oxidized phospholipids was seen in mye-
lin sheaths and in dystrophic axons with disturbed fast axonal
transport. Thus, myelin, oligodendrocytes and injured axons were
those structures showing the most profound accumulation of oxi-
dized epitopes in areas of initial tissue damage. Oxidized lipids
and DNA were also seen in a (small) fraction of astrocytes, in these
cells, however, oxidized lipids were restricted to intracellular (pos-
sibly autophagic) vacuoles. As described by others before, we found
in addition oxidized lipids and some nuclei with oxidized DNA in
macrophages, suggesting the phagocytosis of oxidized tissue deb-
ris. These data strongly support the view that oxidative damage is
an early event inMS tissue injury and amajor driving force in active
MS lesion development. It may play a major role in the induction of
mitochondrial injury, subsequent energy failure and cellular dam-
age [40].
There are several possible sources for ROS and reactive nitrogen
species (RNS) in MS lesions in relation to inﬂammation (Fig. 2).
Production of RNS depend upon functional expression of the nitric
oxide synthases NOS 1-3 [70], whereas ROS are mainly derived
from oxidative burst from activated macrophages and microglia,
involving members of the NADPH oxidase complexes NOX 1–5
[8] or myeloperoxidase, present in activated macrophages and
neutrophils. In addition, mitochondrial injury and dyscoupling of
the respiratory chain may further enhance ROS production and oxi-
dative injury [82]. Finally, iron or related divalent cations may am-
plify oxidative damage by the formation of highly reactive
hydroxyl (OH.). radicals [51]. ROS together with nitric oxide radi-
cals give rise to the highly toxic peroxynitrite intermediates. Perox-
ynitrite is able to inhibit complex I activity, which is crucial for ATP
generation, and complex I activity is strikingly reduced in chronic
MS lesions [71]. Taken together, all these highly reactive molecules
seem to be involved in inducing and amplifying tissue injury in the
initial stage of MS lesion formation but also in their progressive
expansion or in the diffuse injury of the normal appearing white
and grey matter.
Several studies have analysed the expression of inducible NOS
in MS lesions and reported profound expression in activated
microglia and macrophages at the active lesion edge [24,69,115].
In addition, myeloperoxidase immunoreactivity has been seen in
active white matter and cortical lesions in macrophages and
microglia [37,38], although the extent of expression is low and re-
stricted to a small subset of macrophages or microglia [80]. Oxida-
tive burst in activated microglia and macrophages is mainly
Fig. 2. There are several potential sources of reactive oxygen species (ROS) in multiple sclerosis lesions. Activated microglia and macrophages produce ROS through oxidative
burst, involving NADPH – oxidase complexes (NOX 1 and 2). ROS induce mitochondrial injury, which then is an additional source of ROS production through dys-coupling of
the respiratory chain. Finally iron is released from ferritin stores when oligodendrocytes are damaged or destroyed in the lesions. In the presence of H2O2 iron is converted
into Fe++, which generates highly toxic hydroxyl radicals in the presence of ROS through the Fenton reaction.
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ﬁve distinct NOX enzymes have been described of which NOX2 is
thought to be the most important source of superoxide in phago-
cytes. NOX2 is a multi-subunit enzyme complex composed of the
membrane-bound gp91phox and p22phox subunits, which upon
activation are coupled to the cytosolic partners p47phox, p67phox,
p40phox and Rac-GTP to form a functional protein complex that
catalyzes the production of superoxide from oxygen. NOX1 is also
bound to p22phox and interacts with the cytosolic binding part-
ners Noxo1 and Noxa1. Interestingly, evidence is emerging that
NADPH oxidase activation and subsequent ROS formation repre-
sents an important pathway of macrophage/microglia-mediated
neuronal and oligodendrocyte injury [19].
We have recently analyzed the expression of several key sub-
units of the NOX family in well-characterized MS lesions (Fischer
et al in preparation). The transmembrane components p22phox
and p91phox are present in virtually all microglia, irrespective of
lesional activity, but the intensity of their expression is much high-
er in areas of initial tissue injury at the margins of active plaques.
Other components, such as NOX1 and the regulatory components
p47phox and Noxo1 are predominantly expressed in activated
microglia in areas of initial tissue injury. At the active margin of
expanding plaques and less intensely in macrophages in more ad-
vanced active lesions all components were colocalized within the
same population phagocytes, suggesting the expression of fully
functional NOX complexes. These data conﬁrm at the level of MS
lesions, what has been shown before in vitro that activated microg-
lia are capable of radical production through the NOX pathway
[19]. Taken together the current data clearly show that molecules
involved in oxidative burst are highly up-regulated in MS lesions
at sites of active tissue injury, at the same location, where pro-
found DNA and lipid oxidation is observed. In addition, mitochon-
drial injury at these sites may give rise to a further ampliﬁcation of
oxidative damage [82]Age related iron accumulation in the human brain may further
amplify oxidative damage in particular in patients with primary or
secondary progressive disease
MS generally starts as a relapsing-remitting disease, which in
time transforms into progressive disease. About 15 to 20% of the
patients lack a relapsing disease phase, but start with progressive
disease from the onset (primary progressive MS; [72]. While clin-
ical disease is highly variable between patients with relapsing
MS, the clinical course of the disease is surprisingly uniform in pa-
tients who have entered the progressive phase. Furthermore, onset
of steady disease progression, both in patients with primary or sec-
ondary progressive disease, occurs around the same age (age 40–
50), irrespective of previous disease severity or course [21,22].
Inﬂammation is the most predominant feature during the early
(relaping) phases of the disease and declines with aging of the pa-
tients and disease duration [34]. In fact, anti-inﬂammatory or
immunomodulatory treatments are effective in the relapsing stage,
but the beneﬁt is lost when the patients have entered the progres-
sive phase [20]. Despite the lower extent of inﬂammation in the
progressive stage of the disease oxidative damage within the active
or slowly expanding lesions in patients with progressive disease is
quite similar as in lesions of patients, who died at early stages of
the disease [40]. These data suggest that inﬂammation may be-
come less prominent in driving tissue injury in the progressive
stage and that additional possibly age-related mechanisms may
amplify neurodegeneration in this phase of the disease.
One potential candidate for such an ampliﬁcation mechanism is
the age-dependent accumulation of iron in the human brain. In the
normal human brain there is an increasing iron load with aging,
which reaches a plateau at the age of 40 to 50 years, at the time
of average conversion from relapsing to progressive MS [39]. Iron
together with ferritin is predominantly stored in oligodendrocytes
and to a lower degree also in microglia and macrophages [47]. In
MS lesions iron-loaded oligodendrocytes have disappeared,
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iron accumulation is seen at the lesion edges, mainly contained in
macrophages and microglia [23,47]. This is seen in all MS lesions,
irrespective of the stage of the disease, but it is much more pro-
nounced in progressive MS in patients over the age of 40 to
50 years. Thus in the process of oligodendrocyte destruction and
demyelination in MS lesions iron is liberated from its intracellular
ferritin bound stores into the extracellular space, where it is taken
up by microglia and macrophages and again stored together with
ferritin. When this happens in MS lesions in an environment,
where free radicals are produced by oxidative burst, iron can be
liberated from ferritin and transformed into reactive Fe++ [114],
which reacts with hydrogen peroxide to generate highly reactive
hydroxyl radicals [36] and thus ampliﬁes oxidative damage and
associated cellular injury. Although such a mechanism has been
previously proposed for many other neurodegenerative diseases,
it appears to be particularly important in MS lesions due to the nat-
ure of the disease, characterized by profound and preferential
destruction of iron-loaded oligodendrocytes and myelin and by
chronic inﬂammation [62]. Thus this mechanism could massively
amplify oxidative injury and by that augment further demyelina-
tion and – even more importantly – axonal and neuronal
destruction.
From this concept on molecular pathophysiology of tissue in-
jury in MS brains a large array of oportunities for future neuropro-
tective therapies is emerging. Inﬂammation will remain a key
target, since the data suggest that microglia activation and oxida-
tive burst is driven by inﬂammation throughout all stages of the
disease. However, to what extent the cytokine pathways of inﬂam-
mation, so far identiﬁed in classical EAE models, are applicable for
MS is currently uncertain. In addition, it remains a challenge to tar-
get an inﬂammatory process, which is at least in part compartmen-
talized within the CNS behind a closed blood brain barrier.
Regarding neuroprotection the cascade of events could be targeted
at several levels, including the blockade of cytotoxic microglia acti-
vation, reducing radical production, trying to detoxify radicals by
scavengers or augmenting intrinsic anti-oxidant defense mecha-
nisms. Another option would be to reduce the downstream conse-
quences of energy deﬁciency for instance by blockade of ion
transporters or ion exchangers [31,98]. Several of these strategies
are currently tested in MS patients and show promising results.
However, due to the nature of the slowly progressive disease it will
take years before we will be able to judge their long-time efﬁcacy
in patients.
7. Therapeutic strategies aimed at reducing ROS-mediated
injury
Various recent publications have demonstrated that ROS and
concomitant oxidative damage markedly contribute to the initial
and chronic phase of MS. Hence, antioxidant therapies might be
a promising approach to counteract enhanced ROS levels and thus
reduce disease progression. Indeed, experimental studies showed
that exogenous antioxidants, such as ﬂavonoids, a-lipoic acid
[43,93] reduce disease symptoms in animal models of MS, however
extremely high quantities are needed to observe beneﬁcial effects.
In contrast, well-designed clinical studies on antioxidant therapy
in MS patients are rather limited. A main issue to the use of exog-
enous antioxidants is that most antioxidants are not able to cross
the blood-brain barrier. Besides exogenous antioxidants the CNS it-
self is endowed with a powerful antioxidant defense mechanism
consisting of an arsenal of endogenous antioxidant enzymes
[94,108]. Production of these cytoprotective enzymes is regulated
by the transcription factor nuclear factor E2 related factor 2
(Nrf2), which upon activation induces the production of an array
of antioxidant enzymes, including enzymes involved in glutathionesynthesis, NAD(P)H:quinone oxidoreductase 1 and heme oxygen-
ase 1. We previously observed enhanced levels of Nrf2 and Nrf2-
driven antioxidant enzymes in MS lesions predominantly in
astrocytes and inﬁltrated macrophages [102,103,105]. Intriguingly,
no marked increase was observed in oligodendrocytes and neu-
rons. As such the Nrf2 pathway represents an interesting therapeu-
tic target since further activation of this protective system via
speciﬁc Nrf2 activators might counteract oxidative stress and in-
jury under pathological conditions. Importantly, recent studies
demonstrate the efﬁcacy and beneﬁcial effects of Nrf2 activation
by counteracting ROS-mediated injury and cytotoxicity in vitro
and in EAE animals [17,18,52,50,67]. Moreover, clinical trials with
BG12, an oral formulation of dimethyl fumarate, which is known to
enhance Nrf2 activation, reported promising results [53]. These
studies emphasize the need for additional studies as nowadays
several potent Nrf2 activators have been described which might
be interesting therapeutic candidates for future treatment strate-
gies in MS. Taken together, there is ample evidence that ROS play
a cardinal role in MS pathogenesis and clinical studies indicate that
strategies aimed at restoring the delicate redox balance may offer
protection against ROS-induced damage and limit disease
progression.
Despite these promising results a note of caution is necessary.
Recent genetic studies in EAE models in rats have shown that poly-
morphisms in the p47phox molecule, which increase its expres-
sion, ameliorate clinical disease and pathology. Thus, in this
situation a context, which is expected to increase ROS production,
is beneﬁcial in EAE [7]. These data suggest that ROS may play an
important role in controlling the immune response and inﬂamma-
tion, which is independent from mechanisms of tissue injury in the
lesions.
8. Limitations of current experimental models
Obviously it would be of major help to have experimental mod-
els which reﬂect the disease process in MS more accurately and in
the full spectrum of the disease, as such animal models could be
used for testing novel therapeutics and unraveling early molecular
changes that might play a role in disease onset and progression.
Unfortunately the current models only cover fragmented parts of
the entire disease spectrum. Basic principles of leukocyte migra-
tion into the CNS and brain inﬂammation can and have been well
elucidated in models of autoimmune encephalomyelitis [35]. Mod-
els, which allow the study of subtle mechanisms of inﬂammation,
which relate to speciﬁc cell types other than the classical Th1 and
Th17 cells, however, are currently available only to a very limited
degree. Furthermore, for reasons of convenience most studies are
performed in very selected mouse strains, suitable for genetic ap-
proaches, and with very limited sensitization strategies, although
it is established for decades that even in EAE the mechanisms of
inﬂammation and tissue injury widely differ between animal
strains and models. Regarding the above described mechanism
involving oxidative damage and mitochondrial injury the basic fea-
tures can be reproduced in EAE models, as has elegantly been
shown in a recent comprehensive study [84]. However, in direct
comparison the extent of oxidative injury in MS is much more
extensive and pronounced than ever seen in rodent EAE models.
What is completely missing in the models is a comparable degree
of age-dependent iron accumulation in the CNS tissue. In case iron
liberation in the lesions as a major ampliﬁcation mechanism for
ROS-driven neurodegeneration in MS is conﬁrmed, new experi-
mental models have to be developed for preclinical testing of neu-
roprotective strategies. To develop such new models will be of
critical importance, since the evidence provided in this review is
largely based on pathological studies of human autopsy tissue,
which are observational and open to interpretation.
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